NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses

RecruitingNA

Sponsor: Montefiore Medical Center

Conditions: Opioid Use Disorder, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate

Interventions: Standard of Care Referral, Low Threshold Buprenorphine

Countries: United States

This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce opioid cravings and withdrawal symptoms. The study compares two ways of connecting people to treatment: Referral to a community treatment provider (usual care before the new program begins). Onsite, low-threshold buprenorphine treatment at the SSP, which allows participants to start medication quickly and without having to establish care at another provider. Participants will be adults who have opioid use disorder and are SSP clients. Each SSP will begin offering the new onsite buprenorphine program at different times during the study. Researchers will collect information before and after the new program begins to see how it affects treatment engagement and health outcomes. The study will also examine how easy or difficult it is for SSPs to start and run the new program, how acceptable it is to staff and participants, and whether it is cost-effective. The overall goal is to find better ways to expand access to life-saving opioid treatment in community-based settings.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. ≥ 18 years old;
2. Meet DSM-5 criteria for moderate or severe OUD;
3. Interest in receiving buprenorphine treatment;
4. Speaks English or Spanish;
5. Currently an SSP client at the time of enrollment;
6. Ability to provide informed consent.

Exclusion Criteria:

1. Current use of prescribed opioid agonist treatment, as assessed by self-report, at the time of enrollment;
2. Unstable mental health or medical condition that requires an immediate clinical evaluation or higher level of care;
3. Allergy to buprenorphine;
4. Currently detained in jail, prison, residential substance use treatment facility, or other overnight facility as required by court of law. or have pending legal action that could prevent participation on study activities.

Locations (8)

Los Angeles, California, United States
Washington D.C., District of Columbia, United States
Baton Rouge, Louisiana, United States
Duluth, Minnesota, United States
Roswell, New Mexico, United States
Grants Pass, Oregon, United States
Greenville, South Carolina, United States
Milwaukee, Wisconsin, United States